Markers predicting response to complement inhibitor therapy
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study looks for markers that may predict a favorable response to complement inhibitor drugs in people with generalized myasthenia gravis. It aims to identify who might benefit most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of generalized myasthenia gravis and test positive for anti-AChR antibodies.
- Your doctor has recommended complement inhibitor therapy according to approved guidelines.
- You are able to attend follow-up visits at the study center.
- You are willing and able to sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses lab-grown mini muscle-nerve cells (organoids) to better understand severe, hard-to-treat myasthenia gravis. It may help researchers find new treatment options for people with the AChR antibody type.
This study tests a new drug called aritinercept to see if it can help people with generalized myasthenia gravis (a condition where muscles weaken over time). Researchers believe this drug may reduce the immune system activity that causes muscle weakness.
This study uses wearable sensors to track symptoms of myasthenia gravis in daily life. The goal is to see if these devices can better monitor how the disease changes over time.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
This study looks at protein changes in patients with myasthenia gravis who are taking the medication Ravulizumab. By understanding these changes, researchers hope to learn more about the condition and how the treatment works.
This study looks at how the thymus gland and certain antibodies relate to myasthenia gravis, a condition that causes muscle weakness. It may help doctors understand the disease better and could lead to improved treatments.
Hear when a new Myasthenia Gravis, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.